Home › glaxosmithkline
 

Keywords :   


Tag: glaxosmithkline

Would Pfizer Buying GlaxoSmithKline Make Sense?

2015-05-23 05:35:16| Biotech - Topix.net

The Pfizer conundrum What makes this outperformance so unique and strange is the fact that growth stocks are typically the most prominent outperformers during a bull market, while income plays and mature growth opportunities, such as Pfizer, often underperform the broad market. To make matters even more confusing, patent exclusivity losses have hit Pfizer hard.

Tags: make sense buying pfizer

 

GlaxoSmithKline: Out of step

2015-05-12 10:41:13| Biotech - Topix.net

As Britons were voting to choose a new government last Thursday, another election was taking place footsteps from parliament. In the Queen Elizabeth II conference centre opposite Westminster Abbey, shareholders of GlaxoSmithKline gathered to anoint Sir Philip Hampton as new chairman of the UK's biggest drugmaker .

Tags: step glaxosmithkline

 
 

Sunday Newspaper Share Tips: MXC Capital, Aureus MIning, Speedy Hire and GlaxoSmithKline

2015-05-11 02:02:13| Biotech - Topix.net

Every week we round up the Sunday newspaper share tips. This time,MXC Capital, Aureus Mining, Speedy Hire and GlaxoSmithKline The group combines the virtues of an old-fashioned merchant bank with the get-up-and-go of a 21st Century technology business.

Tags: share tips capital sunday

 

GlaxoSmithKline opts to hold on to HIV business

2015-05-06 15:04:10| Biotech - Topix.net

British-based drugmaker GlaxoSmithKline has opted to keep its stand-alone HIV business as it set out its strategy following the completion of its recent deal with Switzerland's Novartis. GSK said it has cancelled an initial public offering of its HIV business, ViiV Healthcare, opting instead to retain its full holding in the joint venture with equity partners Pfizer and Shiongi.

Tags: business hold hiv glaxosmithkline

 

GlaxoSmithKline targets growth across units, scraps ViiV listing

2015-05-06 15:04:09| Biotech - Topix.net

It also scrapped plans to float its HIV drug business ViiV Healthcare, citing its strong outlook, and promised to pay a steady dividend of 80 pence a share over the next three years. Chief Executive Andrew Witty is under pressure to prove to investors that a $20 billion-plus asset swap with Novartis can revive GSK's fortunes, following a damaging slide in lung drug sales and a major corruption scandal in China.

Tags: listing growth units targets

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »